CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce the risk of cardiovascular events and all-cause mortality in patients at high risk of cardiovascular disease (CVD). Due to high costs and unknown long-term adverse effects, critical evaluation of patients considered for PCSK9 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjellmo, Christian Abendstein, Hovland, Anders, Lappegård, Knut Tore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023332/
https://www.ncbi.nlm.nih.gov/pubmed/29861477
http://dx.doi.org/10.3390/diseases6020045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023332/
https://www.ncbi.nlm.nih.gov/pubmed/29861477
http://dx.doi.org/10.3390/diseases6020045

Ejemplares similares